While m6A has emerged as a regulator and potential therapeutic target in pulmonary hypertension,81 to the best of our knowledge—excluding an indirectly-relevant report observing ADAR1 to promote VSMCs proliferation and neointima formation256—no reports currently exist describing A-to-I editing in pulmonary hypertension. Here, ADAR is linked to pulmonary arterial hypertension.